Unknown

Dataset Information

0

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome.


ABSTRACT:

Aims

In our single-center retrospective study we evaluated whether level of different checkpoint molecules in bone marrow biopsies at diagnosis affect the clinical course of patients with myelodysplastic syndrome (MDS).

Methods and results

A consecutive cohort of 55 MDS patients treated in our center from 2003 to 2018 with available bone marrow biopsies at time of diagnosis was studied. We used a technique able to detect the expression of the following antigens: PD-1, PD-L1, PD-L2, LAG-3, Gal-9, TIM-3, CD80. The association between expression level and 3-year overall and relapse-free survival and time-to-progression was analyzed. Intensive expression of TIM-3 was observed in 100% of cases. Also, in most cases, moderate Gal-9 expression was observed. With 3-year follow-up disease progression was seen in 72.9% of patients with high CD80 level and 52.1% of patients with low CD80 level (p=0.04). PD-1, CTLA4 and TIM-3 ligands were co-expressed in the majority of patients. General checkpoint ligand expression level also was associated with increased 3-year incidence of progression: 67.2% of patients with high level of checkpoint ligands progressed, while in the group with low checkpoint ligand expression level progression was observed only in 33.3% of cases (p=0.059). There was an association between the expression of checkpoint molecules CD80, PD-L2, TIM3, the number of bone marrow blasts and risk according to IPSS and IPSS-R scales.

Conclusions

Our preliminary study underlined heterogeneous immune checkpoint molecules expression in MDS and warrants further studies to define the role of this heterogeneity and develop optimal treatment approaches.

SUBMITTER: Tcvetkov N 

PROVIDER: S-EPMC7364161 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3061996 | biostudies-literature
| S-EPMC1867594 | biostudies-literature
| S-EPMC8193904 | biostudies-literature
| S-EPMC8570581 | biostudies-literature
| S-EPMC5564547 | biostudies-literature
| S-EPMC10512514 | biostudies-literature
| S-EPMC4607304 | biostudies-literature
| S-EPMC8525096 | biostudies-literature
2024-10-25 | GSE279914 | GEO
| S-EPMC4372597 | biostudies-literature